Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix (methyl aminolevulinate) photodynamic therapy vs no PDT for onychomycosis
2012-003416-31Phase 3Active
- Sponsor
- Fundación Academia Española de Dermatología y Venereología
- Start
- Jan 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methyl aminolevulinate in onychomycosis (2 arms), sponsored by Fundación Academia Española de Dermatología y Venereología. Primary endpoint: Clinical improvement in Onychomycosis Severity Index (OSI). Started Jan 2013; status: active.
02
Drugs
methyl aminolevulinate
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2012-003416-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003416-31.